Ellagic acid (EA), a phenolic small‐molecule inhibitor of RNase L, can inhibit RNase L ribonuclease activity and consequently attenuate ADAR1‐associated apoptosis, indicating that EA is a viable therapeutic target for AGS with ADAR1 mutations [173]. The gene discussed is ADAR; the disease is Aicardi-Goutieres syndrome.